Literature DB >> 9631086

Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.

Y Reiter1, U Brinkmann, B Lee, I Pastan.   

Abstract

Disulfide-stabilized Fv fragments of antibodies (dsFv) are molecules in which the VH-VL heterodimer is stabilized by an interchain disulfide bond engineered between structurally conserved framework positions distant from complementarity-determining regions (CDRs). This method of stabilization is applicable for the stabilization of many antibody Fvs and has also been applied to a T-cell receptor Fv. A summary of the design strategy, and the construction and production of various dsFvs and dsFv-fusion proteins is presented. Included in the discussion are the biochemical features of dsFvs in comparison with scFvs, the effect of disulfide stabilization on Fv binding and activity, and various applications of dsFvs and dsFv-immunotoxins for tumor imaging and the treatment of solid tumors in animal models.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9631086     DOI: 10.1038/nbt1096-1239

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  42 in total

1.  Single-domain antibody fragments with high conformational stability.

Authors:  Mireille Dumoulin; Katja Conrath; Annemie Van Meirhaeghe; Filip Meersman; Karel Heremans; Leon G J Frenken; Serge Muyldermans; Lode Wyns; Andre Matagne
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles.

Authors:  K Stubenrauch; S Gleiter; U Brinkmann; R Rudolph; H Lilie
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

3.  A modular IgG-scFv bispecific antibody topology.

Authors:  Kelly Davis Orcutt; Margaret E Ackerman; Maryelise Cieslewicz; Emmanuel Quiroz; Adrian L Slusarczyk; John V Frangioni; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2009-12-17       Impact factor: 1.650

4.  Engineering anti-vascular endothelial growth factor single chain disulfide-stabilized antibody variable fragments (sc-dsFv) with phage-displayed sc-dsFv libraries.

Authors:  Yi-Jen Huang; Ing-Chien Chen; Chung-Ming Yu; Yu-Ching Lee; Hung-Ju Hsu; Anna Tung Ching Ching; Hung-Ju Chang; An-Suei Yang
Journal:  J Biol Chem       Date:  2010-01-12       Impact factor: 5.157

5.  Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.

Authors:  Jürgen Schanzer; Andreas Jekle; Junichi Nezu; Adriane Lochner; Rebecca Croasdale; Marianna Dioszegi; Jun Zhang; Eike Hoffmann; Wilma Dormeyer; Jan Stracke; Wolfgang Schäfer; Changhua Ji; Gabrielle Heilek; Nick Cammack; Michael Brandt; Pablo Umana; Ulrich Brinkmann
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

6.  Probing the stability-limiting regions of an antibody single-chain variable fragment: a molecular dynamics simulation study.

Authors:  Ting Wang; Yong Duan
Journal:  Protein Eng Des Sel       Date:  2011-07-05       Impact factor: 1.650

7.  A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.

Authors:  Zhi Liu; Esther C Leng; Kannan Gunasekaran; Martin Pentony; Min Shen; Monique Howard; Janelle Stoops; Kathy Manchulenko; Vladimir Razinkov; Hua Liu; William Fanslow; Zhonghua Hu; Nancy Sun; Haruki Hasegawa; Rutilio Clark; Ian N Foltz; Wei Yan
Journal:  J Biol Chem       Date:  2015-01-12       Impact factor: 5.157

8.  CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

Authors:  Anke Steinmetz; François Vallée; Christian Beil; Christian Lange; Nicolas Baurin; Jochen Beninga; Cécile Capdevila; Carsten Corvey; Alain Dupuy; Paul Ferrari; Alexey Rak; Peter Wonerow; Jochen Kruip; Vincent Mikol; Ercole Rao
Journal:  MAbs       Date:  2016-03-16       Impact factor: 5.857

Review 9.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

10.  Expression of a Functional zipFv Antibody Fragment and Its Fusions with Alkaline Phosphatase in the Cytoplasm of an Escherichia coli.

Authors:  Byung-Ung Hur; Hyo-Jung Choi; Jae-Bong Yoon; Sang-Hoon Cha
Journal:  Immune Netw       Date:  2010-04-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.